We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that Genzyme, the specialty care global business unit of Sanofi (SNY - Free Report) , has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe.
Notably, Fitusiran is an investigational RNA interference (RNAi) therapeutic being developed for the treatment of hemophilia and rare bleeding disorders (RBD).
This expanded right follows Genzyme’s October 2015 decision to opt in to develop and commercialize fitusiran in their rest of world territories.
The companies formed a global alliance in Jan 2014.
The decision to opt in was based on the latest interim clinical results from a phase I study of fitusiran which was presented at the World Federation of Hemophilia (WFH) in July. Supplementary data on fitusiran will be presented at the American Society of Hematology (ASH) meeting in December. Alnylam plans to initiate the fitusiran phase III program in early 2017.
This development-stage biopharmaceutical company is focused on the development of novel therapeutics based on RNAi. Other than Sanofi, the company’s core RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis AG (NVS - Free Report) , Roche Holding AG (RHHBY - Free Report) and Monsanto for Alnylam’s further development and utilization. To promote broader use of the company’s technology, Alnylam is also stepping beyond its primary focus area. These deals not only provide it with funds but also take its RNAi technology outside its main area of focus.
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that Genzyme, the specialty care global business unit of Sanofi (SNY - Free Report) , has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe.
Notably, Fitusiran is an investigational RNA interference (RNAi) therapeutic being developed for the treatment of hemophilia and rare bleeding disorders (RBD).
This expanded right follows Genzyme’s October 2015 decision to opt in to develop and commercialize fitusiran in their rest of world territories.
ALNYLAM PHARMA Price and Consensus
ALNYLAM PHARMA Price and Consensus | ALNYLAM PHARMA Quote
The companies formed a global alliance in Jan 2014.
The decision to opt in was based on the latest interim clinical results from a phase I study of fitusiran which was presented at the World Federation of Hemophilia (WFH) in July. Supplementary data on fitusiran will be presented at the American Society of Hematology (ASH) meeting in December. Alnylam plans to initiate the fitusiran phase III program in early 2017.
This development-stage biopharmaceutical company is focused on the development of novel therapeutics based on RNAi. Other than Sanofi, the company’s core RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis AG (NVS - Free Report) , Roche Holding AG (RHHBY - Free Report) and Monsanto for Alnylam’s further development and utilization. To promote broader use of the company’s technology, Alnylam is also stepping beyond its primary focus area. These deals not only provide it with funds but also take its RNAi technology outside its main area of focus.
SANOFI-AVENTIS Price
SANOFI-AVENTIS Price | SANOFI-AVENTIS Quote
Alnylam and Sanofi both currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>